Triple-Negative Breast Cancer (TNBC) Terminated Phase 1 / 2 Trials for Cisplatin (DB00515)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01918306GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast CancerTreatment